In a recent Securities and Exchange Commission filing, Randall K. Fields, the Chief Executive Officer of ReposiTrak (NASDAQ:TRAK), reported the sale of 7,500 shares of the company’s common stock over two transactions on January 20 and 21, 2026. The aggregate value of these disposals amounted to $81,977. These sales came during a period marked by a significant decline of nearly 40% in TRAK's stock price over the past six months, with shares currently trading around $11.19, close to their 52-week low of $10.69.
On January 20, 2026, Fields sold 2,500 shares at a weighted average price of approximately $10.97 per share, with transaction prices ranging between $10.87 and $11.01. This tranche equated to roughly $27,424 in proceeds. The following day, January 21, Fields executed a second sale of 5,000 shares at an average price near $10.91 each, with sale prices ranging from $10.84 to $10.99, totaling about $54,553.
These shares were indirectly held by RK Fields Charitable 2022, LLC. Post-transaction, this entity continues to maintain an indirect stake of 137,500 shares. In addition to the charitable LLC holdings, Fields personally possesses 3,483,955 shares of ReposiTrak common stock. Further indirect holdings include 615,260 shares through Riverview Financial Corp, 30,667 shares via his spouse, and 333,643 shares held by Fields Management, Inc. Fields also has indirect ownership of preferred stock: 169,797 shares of Series B Preferred Stock through Riverview Financial Corp and 3,704 shares through his spouse.
The CEO’s stock sales were completed under a pre-determined Rule 10b5-1 trading plan, a mechanism designed to facilitate stock sales while complying with insider trading regulations. The purpose of these disposals was to fulfill charitable obligations, rather than signaling a shift in corporate confidence.
Despite the downward price trajectory, ReposiTrak’s financial fundamentals remain robust. The company reports impressive gross profit margins of 84.11% alongside a strong liquidity position, with a current ratio of 6.54, indicating that its liquid assets substantially exceed short-term liabilities. The balance sheet is further strengthened by a cash position that surpasses outstanding debt.
Analyses from InvestingPro indicate that ReposiTrak is currently undervalued relative to its fair value, with a recognized price target of $29 per share. Investors looking for additional insights and guidance on TRAK and other equities can access InvestingPro’s extensive research and investment tips.
Operationally, ReposiTrak reported a 10% increase in revenue during the first fiscal quarter of 2026, attaining $6 million. GAAP net income rose 13% to $1.8 million, yielding earnings per share of $0.10 basic and $0.09 diluted. Further enhancing shareholder value, ReposiTrak declared a quarterly dividend of $0.02 per share or $0.08 annually, with distributions anticipated in February 2025.
The corporate strategy includes the approval of a new Rule 10b5-1 share repurchase plan authorizing up to $2 million in buybacks, part of a broader $21 million repurchase program aimed at returning capital to shareholders. The recent annual meeting saw the re-election of Randall K. Fields and directors Robert W. Allen, Ronald C. Hodge, and Peter J. Larkin.
Additionally, ReposiTrak continues to expand its Traceability Network, with several food manufacturers preparing to join, bolstering adherence to FDA data exchange regulations. These initiatives underscore the company’s commitment to strengthening its financial position and expanding operational capabilities.